Abstract: Provided is a fast dissolving film composition comprising a medically active component as an active ingredient, in which the bitter taste of the active ingredient is masked and the fast dissolving film composition has a high content of 50% or higher. More particularly, provided is a pharmaceutical composition which comprises sildenafil or pharmaceutically acceptable salts thereof as an active ingredient, and which comprises a combination of a specific bitter taste masking agent to achieve masking of a bitter taste. Further, provided is a fast dissolving film composition which comprises a combination of a specific plasticizer to mask a bitter taste, and in which the physical properties of the high-content film are excellent.
Type:
Grant
Filed:
February 28, 2013
Date of Patent:
October 9, 2018
Assignee:
SEOUL PHARMA CO., LTD.
Inventors:
Hyun Jun Jeong, Ik Hyeon Chang, Dal Geun Kim, Jin Hoo Lee, Jin Hee Um, Hyun Soo Kim, Kyung Tae Jung, Kyu Jeong Yeon, Jin Gyu Park
Abstract: Provided is a fast dissolving film composition comprising a medically active component as an active ingredient, in which the bitter taste of the active ingredient is masked and the fast dissolving film composition has a high content of 50% or higher. More particularly, provided is a pharmaceutical composition which comprises sildenafil or pharmaceutically acceptable salts thereof as an active ingredient, and which comprises a combination of a specific bitter taste masking agent to achieve masking of a bitter taste. Further, provided is a fast dissolving film composition which comprises a combination of a specific plasticizer to mask a bitter taste, and in which the physical properties of the high-content film are excellent.
Type:
Application
Filed:
February 28, 2013
Publication date:
January 22, 2015
Applicant:
SEOUL PHARMA CO., LTD
Inventors:
Hyun Jun Jeong, Ik Hyeon Chang, Dal Geun Kim, Jin Hoo Lee, Jin Hee Um, Hyun Soo Kim, Kyung Tae Jung, Kyu Jeong Yeon, Jin Gyu Park
Abstract: The present invention relates to new heterocyclic compounds containing nitrogen atoms or pharmaceutically acceptable salts thereof, a process for the preparation thereof, and a pharmaceutical composition comprising the same for treatment of cancer. The compounds according to the present invention induce DNA damage due to reactive oxygen species to activate c-abl and p53, induce RhoB to generate apoptosis, and induce cell death by down-regulating Bcl2 involved in cell survival, which is generated by dysregulated signals via the mitochondria pathway, thereby inhibiting tumor cell growth and inducing apoptosis. Accordingly, the composition according to the present invention can be used to treat cancer.
Type:
Application
Filed:
August 10, 2007
Publication date:
June 10, 2010
Applicants:
Korea Research Instititute of Bioscience and Biotechnology, Seoul Pharma, Co., Ltd.
Inventors:
Gyoon Hee Han, Eun Hyun Choi, Jee Sun Yang, Sung Hee Hong, Myung Sook Kim, Mi Sun Won, Kyung Sook Chung, Dong Myung Kim, Hyang Sook Yoo, Hwan Mook Kim, Song Kyu Park, Ki Ho Lee, Chang Woo Lee, Youn Woong Choi, Yong Mi Jeong, Byung Gu Min
Abstract: The present invention relates to a controlled-release niacin formulation. In particular, the present invention relates to a controlled-release niacin formulation, comprising niacin; hydroxypropyl methylcellulose; and a carboxyvinyl polymer, in which the carboxyvinyl polymer and hydroxypropyl methylcellulose are contained in a predetermined weight ratio, and to a preparation method thereof. The controlled-release niacin formulation according to the present invention maintains its matrix shape until completion of release, and maintains its release pattern without fluctuation for a desired time period, unlike a commercial formulation. In particular, since niacin formulations are used for long-term treatment of hyperlipidemia, the controlled-release niacin formulation of the present invention, capable of maintaining effective blood concentration and high stability for a long period of time, is very useful.
Type:
Application
Filed:
July 28, 2008
Publication date:
March 12, 2009
Applicant:
SEOUL PHARMA. CO., LTD.
Inventors:
Youn Woong CHOI, Byung Hwan RYOO, Yong Mi JEONG, Jae Sang JANG